Evidence map›Paper›PMID 34699319›Full record

ArticleBioengineered2021

Cullin3 (CUL3) suppresses proliferation, migration and phenotypic transformation of PDGF-BB-stimulated vascular smooth muscle cells and mitigates inflammatory response by repressing Hedgehog signaling pathway.

Yuluan Xiang, Lihua Li, Shuang Xia, Jinlin Lv, Xiaoling Li

Open access · goldAbstract readVideo-Audio Media
In one paragraph

Article in Bioengineered, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
0.5field-weighted citation impact, top 37% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 10 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Receptor Tyrosine Kinase: Still an Interesting Target to Inhibit the Proliferation of Vascular Smooth Muscle Cells.American journal of cardiovascular drugs : drugs, devices, and other interventions · 2023
    Review
  5. Article
  6. Article
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 3 institutions in 1 country.

Yuluan XiangDepartment of Gerontology and Special Medical Services, The First Affiliated Hospital of Dali University, Dali, Yunnan, China.
Lihua LiDepartment of Gerontology and Special Medical Services, The First Affiliated Hospital of Dali University, Dali, Yunnan, China.
Shuang XiaGuangdong Cardiovascular Institute, Guangdong General Hospital, Guangdong Academy of Medical Sciences, Guangzhou, Guangdong, China.
Jinlin LvDepartment of Gerontology and Special Medical Services, The First Affiliated Hospital of Dali University, Dali, Yunnan, China.
Xiaoling LiDepartment of Cardiovascular Medicine, People's Hospital of Fengjie, Chongqing, China.
Dali University · CNFirst People's Hospital of Chongqing · CNGuangdong Academy of Medical Sciences · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Vascular smooth muscle cell (VSMC) hyperplasia is closely associated with AS progression. Hence, it is of great significance to elucidate the molecular mechanisms underlying the involvement of VSMCs in AS. SHH antagonist can inhibit the excessive proliferation, migration and phenotypic transformation of PDGF-BB-induced VSMCs. It has been proved that CUL3 can suppress Hedgehog signaling. This current work was designed to identify the biological role of CUL3 in the behaviors of VSMCs in AS and investigate the potential molecular mechanism. VSMCs were treated with PDGF-BB to establish the cell model

Indexed as

Cell MovementCell ProliferationSignal TransductionBecaplerminCullin ProteinsHedgehog ProteinsHumansMuscle, Smooth, VascularMyocytes, Smooth MuscleBecaplerminCUL3 protein, humanCullin ProteinsHedgehog ProteinsatherosclerosisCullin3Hedgehog pathwayVSMCs

Identifiers

PMID34699319
PMCPMC8809906
OpenAlexW3208680691

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.